Large-scale sequencing has characterized an enormous number of genetic variations (GVs), and the functional analysis of GVs is fundamental to understanding differences in disease susceptibility and therapeutic response among and within populations. Using a combination of a sequence-based predictor with known phosphorylation and protein-protein interaction information, we computationally detected 9606 potential phosSNPs (phosphorylation-related single nucleotide polymorphisms), including 720 known, disease-associated SNPs that dramatically modify the human phosSNP-associated kinase-substratekinase-substrate network. Further analyses demonstrated that the proteins in the network are heavily associated in various signaling and cancer pathways, while cancer genes and drug targets are significantly enriched. We re-constructed four population-specific kinase-substrate networks and found that several inherited disease or cancer genes, such as IRS1, RAF1, and EGFR, were differentially regulated by phosSNPs. Thus, phosSNPs may influence disease susceptibility and be involved in cancer development by reconfiguring phosphorylation networks in different populations. Moreover, by systematically characterizing potential phosphorylation-related cancer mutations (phosCMs) in 12 types of cancers, we observed that both types of GVs preferentially occur in the known cancer genes, while a considerable number of phosphorylated proteins, especially those over-representing cancer genes, contain both phosSNPs and phosCMs. Furthermore, it was observed that phosSNPs were significantly enriched in amplification genes identified from breast cancers and tyrosine kinase circuits of lung cancers. Taken together, these results should prove helpful for further elucidation of the functional impacts of disease-associated SNPs.
Introduction
In the post-genomic era, the large-scale identification of human genetic variations (GVs) is critically important for an understanding of the differences in both the susceptibility to diseases and response to therapeutic treatment (Manolio et al., 2008; Ren et al., 2010; Gunther et al., 2011; Gonzaga-Jauregui et al., 2012) . After over a decade of effort, the HapMap Project, the 1000 Genomes Project, Cancer Genome Project, and other similar projects have identified an enormous number of individual GVs, such as germline single nucleotide polymorphisms (SNPs), somatic mutations and structural variants (Greenman et al., 2007; Manolio et al., 2008; 1000 Genomes Project Consortium, 2010 Forbes et al., 2010) . Although most GVs may be incidental and not alter gene function (Collins et al., 1998) , genome-wide association (GWA) studies have recently detected tens of thousands of GVs that are associated with a variety of diseases (Manolio et al., 2008; Stenson et al., 2009; Li et al., 2012b) . SNPs in the coding region (cSNPs), especially non-synonymous SNPs (nsSNPs), are significantly associated with certain specific phenotypes and diseases (Cargill et al., 1999; Gunther et al., 2011) . Additionally, a considerable proportion of somatic mutations have been predicted to be "cancer drivers" that advance disease progression (Greenman et al., 2007; Carter et al., 2009; Vandin et al., 2012; Reimand and Bader, 2013) . In this regard, characterizing the functional consequences of GVs is of critical importance to understand individual genetic differences, thus supporting the concept of "personalized medicine" (Ren et al., 2010; Gonzaga-Jauregui et al., 2012) .
It is well documented that nsSNPs generate deleterious effects by modifying protein structural conformation (Reumers et al., 2006; Yue and Moult, 2006) . However, nsSNPs also influence the post-translational modifications (PTMs) of proteins (Savas and Ozcelik, 2005; Erxleben et al., 2006; Gentile et al., 2008; Radivojac et al., 2008; Yang et al., 2008a; Ryu et al., 2009; Li et al., 2010) . For example, Savas and Ozcelik (2005) predicted that 15 nsSNPs potentially create or remove phosphorylation sites in cell-cycle and DNA repair proteins.The Armstrong group first suggested the concept of aberrant phosphorylation or "phosphorylopathy" caused by GVs in 2006 (Erxleben et al., 2006) and predicted 16 phosphorylopathies in human ion channel genes (Gentile et al., 2008) . One of the predicted results, a K897T nsSNP in the human ether-a-gogo-related gene 1 (hERG1), was experimentally shown to generate a novel Akt phosphorylation site that inhibited (Gentile et al., 2008) . Subsequently, Yang et al. (2008a) mapped cSNPs to flanking regions of known phosphorylation sites and proposed that 64 of them were potentially disrupted by nsSNPs. Recently, systematic analysis of inherited disease-or cancer-associated GVs that potentially alter protein phosphorylation has emerged as an important undertaking (Radivojac et al., 2008; Ryu et al., 2009; Li et al., 2010; Reimand and Bader, 2013) . Ryu et al. (2009) predicted that both nsSNPs and somatic mutations are implicated in various cancers and inherited diseases by changing phosphorylation. Also, Radivojac et al. (2008) showed that phosphorylation-associated mutations are significantly enriched in cancers and inherited diseases compared with germline nsSNPs, and further observed that loss of PTM sites might be an important mechanism in these diseases (Li et al., 2010) . Furthermore, found that a cancer-patient-derived mutation R81T on Sin1 impairs the Sin1 phosphorylation, which leads to the hyper-activation of mTORC2 and facilitates tumorigenesis. In addition, Reimand and Bader (2013) developed a statistical approach termed ActiveDriver, and predicted 44 potential cancer driver genes with significant phosphorylation-associated single-nucleotide variants (pSNVs) from nine cancer data sets. Taken together, these studies showed that GVs, such as mutations and SNPs, might contribute to the development of cancers or inherited diseases through the reconfiguration of phosphorylation signaling.
Previously, we defined phosSNP (phosphorylation-related SNP) as an nsSNP that influences the protein phosphorylation state (Ren et al., 2010) , with the concurrence of Dr David L. Armstrong in the form of personal communications. Using the kinase-specific predictor of GPS 2.0 (Xue et al., 2008) , we directly predicted phosphorylation sites in both original and nsSNP-containing sequences (Ren et al., 2010) . By comparison of the prediction results, we identified a total of ~70% of the nsSNPs as potential phosSNPs. However, because only a small proportion of serine, threonine, and tyrosine residues can be phosphorylated in vivo, ab initio prediction of phosphorylation sites merely from primary sequences is error-prone. Thus, more filters are needed to be included to reduce the false positive predictions.
In this work, we first predicted the exact kinase information for the original and nsSNP-containing protein sequences by manually forming links of the 407 human kinases with their corresponding predictors in GPS 2.1 (Song et al., 2012) . To improve the accuracy of this process, we only considered potential phosSNPs that change known phosphorylation sites, using experimentally identified phosphorylation sites as a highly efficient filter. Because the short motifs around phosphorylation sites do not provide full recognition specificity for kinases in vivo, the proteinprotein interactions (PPIs) between kinases and substrates were adopted as an additional filter to remove false positive hits. With this procedure, a total of 9606 potential phosSNPs in 7946 proteins were identified with a high degree of confidence. Then we re-constructed the human phosSNP-associated kinase-substrate phosphorylation network and found the network topology to be dramatically changed by phosSNPs. Also, cancer genes and drug targets were significantly over-represented in the network, with the proteins in the network being heavily implicated in a number of signaling and cancer pathways. Furthermore, we observed that the known inherited disease-or cancer-associated mutations were significantly over-represented in the predicted phosSNPs, with a two-fold enrichment. The strong relation between phosSNPs and diseases suggested that phosSNPs may be associated with human disease by reconfiguring the phosphorylation network. Moreover, a number of disease-or cancer-associated genes were found to be differentially regulated by phosSNPs in different populations. Thus, phosSNPs may influence disease and cancer susceptibility by differentially altering the phosphorylation networks in different populations in different regions. In addition, we further systematically analyzed phosphorylation-related cancer mutations (phosCMs) in 12 types of cancer samples. Although both phosCMs and phosSNPs significantly occur more frequently in cancer genes, the known cancer genes were found to be significantly over-represented in phosSNP-containing proteins in most types of cancers. Thus, our results suggest that phosSNPs, along with phosCMs, may be involved in driving cancer progression. Taken together, our results provide help for further experimental analysis of the molecular mechanisms of known disease-associated phosSNPs as well as new leads for personalized medicine. 
Results

Systematic characterization of phosSNPs with a high degree of confidence
In this work, three major improvements were introduced to improve the prediction accuracy of human phosSNPs (Figure 1 ). First, GPS 2.1 hierarchically clustered homologous kinases into the categories of group, family, and subfamily, but did not predict the exact kinase information for a given residue (Xue et al., 2011) . Previously, we manually selected 407 human kinases for 56 serine/threonine kinase (STK) and 21 tyrosine kinase (TK) specific predictors (Song et al., 2012) .
Thus, from 1060070 nsSNPs, we directly predicted raw phosSNPs that exhibited changed phosphorylation patterns because of specific kinases (Figure 1 ). Second, PhosSNP 1.0 contained too many results, most phosphorylation sites of which were ab initio predicted merely from the primary sequences (Ren et al., 2010) . Since recent phosphoproteomic experiments have identified ten thousands of phosphorylation sites (Song et al., 2012) , this information was used to filter out the false positive hits ( Figure 1) . As previously described, we defined a phosphorylation site peptide PSP(15, 15) as a phosphorylation site flanked by 15 residues upstream and 15 residues downstream (Ren et al., 2010; Xue et al., 2011) . We retrieved all PSP(15, 15) items from the phosphorylation data set, and exactly mapped them to the original and mutated RefSeq proteins, respectively. The PSP(15, 15) items that could not be mapped to any SNP were discarded. Then for a specific SNP, the phosphorylation states of original and mutated PSP(15, 15) were further compared. We considered a SNP as a phosSNP only if it could induce the phosphorylation change of the PSP(15, 15), such as creating or abolishing the phosphorylation site, or changing the kinase type of the phosphorylation site (Figure 1 ). Previously, our analyses suggested that the physical interaction between a kinase and a substrate efficiently improves the prediction accuracy of site-specific kinase-substrate relations (ssKSRs) (Song et al., 2012) . Thus, both experimentally identified and pre-predicted PPIs (Exp. & STRING PPIs) were used as an additional filter. We only preserved phosSNPs that change the ssKSRs supported by the PPI information (Figure 1 ). These phosSNPs were classified into different types based on the definitions. In total, we computationally identified 9606 phosSNPs in 7946 RefSeq sequences (Figure 1 ).
In the absence of any filters, approximately 57.2% of the total nsSNPs (606321/1060070) were predicted to be phosSNPs by GPS 2.1 (Table 1) . This result is moderately lower than the one in 7 our previous analysis (Ren et al., 2010) . When known phosphorylation information was considered, only 40344 nsSNPs (~3.8%) were predicted to be phosSNPs (Table 1) . Thus, it is evident that a large proportion of potentially false positive hits were filtered out. The predicted number was further reduced to 9606 (Exp. & STRING PPI, 0.91%) and 2496 (Exp. PPI, 0.24%) using the different PPI data sets (Table 1) . Because the Exp. PPI filter was too stringent and only a small number of hits were predicted, we used the predicted results obtained with Exp. & STRING PPI as the core data set for further analyses.
PhosSNPs dramatically reconfigures the human kinase-substrate phosphorylation network
Kinases can phosphorylate substrates and be also modified by other kinases. Thus, a kinase -substrate phosphorylation network can be re-constructed from ssKSRs between kinases and substrates (Song et al., 2012) . Because site-specific phosphorylation is the result of upstream regulatory kinases (Nilsson, 2012) , phosSNPs reconfigure the human kinase-substrate network by either creating new or disrupting the original ssKSRs. However, because a substrate can be phosphorylated by a kinase at multiple sites, adding or removing one ssKSR does not disrupt the kinase-substrate relation (KSR) if multiple ssKSRs exist. In this regard, the impact of phosSNPs on the kinase-substrate network is classifiable into four types: (i) Added (+), one or multiple new ssKSRs were introduced into an unrelated kinase-substrate pairing; (ii) Removed (-), all existing ssKSRs in a kinase-substrate pair were disrupted; (iii) Changed (C), the KSR was not changed by either adding or removing one or multiple ssKSRs; (iv) Unchanged (N), all the ssKSRs were identical in the original and mutated proteins. From the network results, it is evident that a considerable proportion of KSRs were added (2989, ~16.6%) or removed (4322, ~23.9%) by phosSNPs (Figure 2) . Also, although the KSRs were retained, a number of KSRs (6582, ~36.5%) were changed by adding or removing ssKSRs ( Figure   2 ). Only a proportion of KSRs (4163, ~23.1%) were not influenced (Figure 2 ). In addition, statistical analysis suggested that the topological features of the kinase-substrate phosphorylation networks for the original and mutated proteins were significantly different (Table 2) . Taken together, the results indicate that the human kinase-substrate network was dramatically reconfigured by the phosSNPs.
The phosSNP-associated kinase-substrate network is highly associated with various cancers
In a network, highly connected genes, known as hubs, usually play central roles in mediating the signal communication or exchange in multiple pathways (Jin et al., 2007; Wang et al., 2007; Zaman et al., 2013) . From the phosSNP-associated kinase -substrate network, the top 10 substrates ( Figure 3A ) and kinases ( Figure 3B ) with most KSRs were shown, respectively. If the substrates are also kinases, only directed KSRs from other kinases to these kinases were considered. These genes act as hubs in the network, and their functions might be greatly influenced by the reconfiguration of KSRs. For example, EGFR, the substrate with the most KSRs, was implicated in signaling transduction from extracellular into appropriate cellular responses including regulated growth, proliferation, and survival (Hochgrafe et al., 2010) (Figure 3A ). Previously, a structural modeling study suggested that a SNP of rs17290699 might disrupt the hydrogen and ion bonds between H988 and E690, and further influence EGFR dimer formation (Choura et al., 2010) . Also, IRS1 is a signaling adapter involved in biological processes such as apoptosis, cell growth, and cell transformation through the regulation of insulin signaling (Chang et al., 2002) (Figure 3A ), while mutations in IRS1 have been reported to be implicated in diabetes mellitus type 2 and cancers (Stenson et al., 2009; Hochgrafe et al., 2010) . Among top 10 kinases, AKT1, which has the most KSRs, regulates various processes including metabolism, proliferation, and angiogenesis ( Figure   3B ). The aberrant signaling of AKT was involved in a variety of complex diseases (Manning and Cantley, 2007) . Taken together, the KSRs of hub genes were preferentially changed by phosSNPs, which may contribute to the reconfiguration of signaling pathways and further contribute to the cancers or other diseases.
In addition, we found that 199 (~7.5%) and 219 (~8.3%) genes of the network are cancer genes, using the different cancer gene data sets ( Figure 3C ). Nearly 20% of the network proteins are drug targets ( Figure 3C ). With the hypergeometric distribution, the statistical results suggested that both the cancer genes and drug targets are significantly enriched in the phosSNP-associated kinase -substrate network ( Figure 3C , p-value << 0.01). Although the protein kinases are known to be highly associated with cancer (Haber and Settleman, 2007) , excluding the kinases from the phosSNP-associated kinase-substrate network still resulted in a strong correlation between the phosSNP-containing proteins and cancer genes or drug targets (Supplementary Table S1 , p-value << 0.01). Previously, using a combination of the sequence-based predictions and the PPI information, we predicted a total of 192756 ssKSRs at 25962 human phosphorylation sites, and constructed a human protein phosphorylation network (PPN) among 380 kinases and 4140
substrates (Song et al., 2012) . Indeed, cancer genes and drug targets were shown to be significantly enriched in the PPN against the human proteome (p-value << 0.01), probably because the phosphorylation is highly involved in a variety of signaling processes and highly associated with cancers and diseases. However, using the human PPN as the background, it is evident that phosSNPs are able to further enrich cancer genes ( Figure 3D , p-value < 0.01).
We statistically analyzed the distribution and diversity of Gene Ontology (GO) terms for proteins in the phosSNP-associated kinase-substrate network with the hypergeometric distribution (p-value < 1E-15). The results suggest that network proteins are significantly over-represented in a broad spectrum of biological processes and functions, such as protein phosphorylation, signal transduction, and apoptotic processes (Supplementary Table S2 ). Also, by mapping network proteins to the pathways of the Kyoto Encyclopedia of Genes and Genomes (KEGG), the statistical results indicated that these proteins were significantly associated with a number of cancer pathways, such as pathways in cancer (p-value = 5.69E-23), chronic myeloid leukemia (p-value = 7.56E-23), glioma (p-value = 3.07E-18), and prostate cancer (p-value = 2.30E-17) (Table 3) . Again, we observed that cancer-associated pathways were still significantly enriched even after excluding protein kinases from the network proteins (Supplementary Table S3 ). Moreover, the statistical enrichment analysis of the Disease Ontology (DO) terms suggested that network proteins were significantly enriched in a number of diseases and cancers (Supplementary Table S4 ). In particular, the top 3 most significant DO terms were cancer (p-value = 2.53E-146), breast cancer (p-value = 1.8E-60), and prostate cancer (p-value = 1.31E-47) (Supplementary Table S4 ). In addition, the protein complexes were computed from the network by MCODE v1.32 in Cytoscape (Bader and Hogue, 2003) . The enrichment analysis of the KEGG pathways was performed for the proteins in each of the complexes (Supplementary Table S5 ). The top 4 complexes with the highest scores were shown, with three of them associated with cancers (Supplementary Figure S1 ). Taken together, several lines of evidence suggest that the proteins in the human phosSNP-associated kinasesubstrate network are highly associated with cancer.
PhosSNPs are associated with known human diseases
We classified all predicted phosSNPs into four types (I, II, III, and IV) ( Table 1) , and several typical examples are shown in Figure 4 . In total, it was found that up to 720 unique phosSNPs (~7.4%) were included in the ClinVar, a public resource of relations among GVs and human phenotypes (Landrum et al., 2014) . With the hypergeometric distribution, the p-value was calculated to be 1.19E-81 (the enrichment ratio = 2.18), which suggests that phosSNPs are significantly involved in human diseases (Supplementary Table S6 ). In our results, the G691S nsSNP (rs1799939) in RET was reported to be associated with primary vesicoureteral reflux (pVUR) in the Quebec patients by removing the S691 phosphorylation site (Yang et al., 2008b) . Here, we predicted it as a Type I (+) phosSNP to generate a new phosphorylation site for PKCA ( Figure 4A ). Also, it is known that NF-κB inhibitor α (NFKBIA) is phosphorylated by the IκB kinase at S32, while an S32I nsSNP (rs28933100) removes the phosphorylation site and enhances its inhibitory activity that is associated with autosomal-dominant ectodermal dysplasia with immunodeficiency (AD-EDA-ID) (Courtois et al., 2003) . Consistent with the experimental observation (Courtois et al., 2003) , we predicted it to be a Type I (-) phosSNP that removes the S32 phosphorylation site of IKKB ( Figure 4B ). By mapping the prediction results to the GWASdb (Li et al., 2012b) , we also observed that 10 non-redundant phosSNPs in 10 genes are significantly associated with human diseases (Table 4) . For example, MLXIPL, a carbohydrate-responsive element-binding protein, was previously identified as being associated with metabolic disorders, with an nsSNP of A358V (rs35332062) (Kettunen et al., 2012) .
Here, we predicted it to be a Type II (-) phosSNP as the result of inhibiting the PKACA-mediated phosphorylation at S361 ( Figure 4D ). The predictions for BCL10 ( Figure 4C ), SPTBN1 ( Figure 4E ), and EGFR ( Figure 4F ) still remain to be validated. Taken together, phosSNPs are highly associated with human diseases and useful for further experimental investigation.
PhosSNPs differentially reconfigure the phosphorylation network in different populations
By directly mapping, 1320 predicted phosSNPs were detected from the 1000 Genomes Project (Supplementary Table S7 ). Based on the allele frequency information, we first constructed four population-specific phosSNP-associated kinase -substrate networks for the Ad Mixed American (AMR), East Asian (ASN), African (AFR), and European (EUR), respectively (Table 5 and Supplementary Figure S2) . PhosSNPs without any information on the allele frequencies were not considered in any network. In the four networks, there were 1525-2368 KSRs among 286-303 kinases and 265-392 non-kinase substrates (Table 5) . Also, nearly half of the kinases in these networks were predicted not having any phosSNPs. This result is similar with to that from the analysis for the integrative phosSNP-associated kinase-substrate networks. In particular, only a limited proportion of KSRs (34.9%-38.0%) were not influenced (Table 5) . By statistically analyzing the MCC and degree distributions for the original and mutated proteins, we observed that phosSNPs dramatically altered all population-specific networks (p-value << 0.01, Wilcoxon signed-rank test, Table 5 ).
To test whether phosSNPs differentially influenced the phosphorylation networks in different populations, we calculated the network proteins in a pairwise manner for the KSRs among the four networks. With Yates' chi-squared test, the KSRs of 30 proteins were determined significantly different in at least a pair of populations (Supplementary Table S8 , p-value < 0.01), with the results shown in Table 6 (p-value < 1E-4). In our results, the gene with the greatest number of different KSRs is IRS1 (insulin receptor substrate 1) between the populations of AFR and EUR (Table 6 , p-value = 3.74E-14). The KSRs of IRS1 are also differentially present for AMR-EUR (p-value = 1.42E-08), AFR-ASN (p-value = 6.54E-08), and AMR-ASN (p-value = 4.76E-04) (Table 6 and   Supplementary Table S8 ). As a known drug target (Reimand and Bader, 2013) , IRS1 plays a critical role in apoptosis, cell growth, and cell transformation by regulating insulin signaling (Chang et al., 2002) , and a number of mutations in IRS1 have been shown to be associated with diabetes mellitus type 2 or noninsulin-dependent diabetes mellitus (NIDDM) from the ClinVar annotations (Landrum et al., 2014) . From the SNPs of the 1000 Genomes Project, we predicted up to 9 nsSNPs in IRS1 to be phosSNPs (Supplementary Table S7 Table S7 ), were annotated as diabetes-associated mutations (Supplementary Table S6 ). The former phosSNP, rs148962208, was first identified in a Chinese population and the authors suggested that the hydrophobic to hydrophilic substitution of P1079S may impair the function of IRS1 by inducing a conformational change of its 3D structure (Zeng et al., 2000) . However, our results predicted rs148962208 to be a Type II (-) phosSNP that potentially changes the phosphorylation motif pS-P into pS-S and disrupts the phosphorylation of its adjacent site S1078 by mTOR and CDK5. Because this SNP was not detected in other populations (Supplementary Table S7 ), its effect on IRS1 phosphorylation might be exclusive to the ASN population. The second phosSNP, rs1801276, was mainly identified in the EUR population, such as Danish and French Caucasians (Celi et al., 2000) . It was proposed that the A512P SNP alters the secondary structure of IRS1 by disrupting the α-helix formation (Celi et al., 2000) , whereas our predictions suggested that A512P inhibits the adjacent phosphorylation status of S503.
In addition, the well-characterized cancer gene EGFR was predicted to be differentially regulated by phosSNPs in different pairs of populations (Table 5) . Interestingly, a structural modeling study suggested that rs17290699 (H988P, allele frequency: 0.03 in EUR, Supplementary Table S7) may influence EGFR dimer formation by disrupting the hydrogen and ion bonds between H988 and E690 (Choura et al., 2010) . However, our results indicate that the SNP may also induce the phosphorylation of the adjacent S991 site that is potentially modified by MAPKs. Taken together, although in previous studies, the functional effect of nsSNPs has usually been attributed to their influence on protein structure, our results suggest that they also influence inherited diseases as well as cancer susceptibility by reconfiguring phosphorylation networks.
PhosSNPs as well as phosCMs may be involved in driving cancer progression
To investigate whether phosSNPs are involved in driving cancer progression, we systematically analyzed missense cancer mutations (CMs) in 12 types of cancers, including uterine corpus endometrial carcinoma (UCEC-US), colon adenocarcinoma (COAD-US), lung squamous cell carcinoma (LUSC-US), acute myeloid leukemia (LAML-KR), breast cancer (BRCA-US), rectum adenocarcinoma (READ-US), kidney renal clear cell carcinoma (KIRC-US), liver cancer (LINC-JP), brain glioblastoma multiforme (GBM-US), ovarian serous cystadenocarcinoma (OV-US), breast triple negative/lobular cancer (BRCA-UK), and pancreatic cancer (PACA-CA). Using the human proteome as the background, we observed that known cancer genes (from the Cancer Gene Census) were significantly enriched in missense CM-containing proteins for all cancer types ( Figure 5 , p-value < 0.05). In particular, approximately 400 cancer genes were found to be mutated in the UCEC-US samples, and even in PACA-CA, there were still ~100 mutated cancer genes ( Figure 5 ). Thus, the results supported the hypothesis that missense CMs can be "hotspots" of mutations that are drivers of cancer (Greenman et al., 2007; Haber and Settleman, 2007; Carter et al., 2009) . Furthermore, by predicting potential phosCMs from missense CMs, we demonstrated that phosCM-containing proteins significantly enrich cancer genes, although different levels of significance were observed in different cancer types ( Figure 5 ). For example, the p-value of the cancer genes over-represented in phosCM-containing proteins is < 1E-20 in UCEC-US, but only <0.05 in LUSC-US, LAML-KR, READ-US, GBM-US, OV-US, BRCA-UK, and PACA-CA ( Figure 5 ). In this regard, our analyses suggest that mutated phosphorylation signaling pathways are involved in cancer progression (Reimand and Bader, 2013) and predicted phosCMs to be novel cancer drivers.
Interestingly, the comparison of population-specific phosSNPs and cancer type-specific phosCMs demonstrated that the p-values are more stringent in PhosSNP-containing proteins in the case of enriched cancer genes ( Figure 5 ). It is only in UCEC-US and COAD-US that the number of the enriched cancer genes of phosCMs is greater than phosSNPs ( Figure 5 ). Thus, these statistical analyses suggest that phosSNPs might also be involved in driving cancer progression. Moreover, we re-constructed the kinase-substrate network containing the regulatory kinases as well as the phosSNP-and phosCM-containing proteins for each cancer type based on the predicted KSRs ( Figure 6 ). Clearly, these proteins are tightly connected in the networks, and there are a considerable proportion of substrates containing both phosSNPs and phosCMs ( Figure 6 ). In addition, by comparing phosSNP-and phosCM-containing proteins, we found that many cancer genes contained both genetic variations (Supplementary Figure S3) . Taken together, distinguishing phosSNP-and phosCM-containing proteins from the kinase-substrate networks is difficult, and our results suggest that both phosSNPs and phosCMs have a potential role in driving cancer progression. In this study, we tried to dissect the relationships between phosSNPs and gene amplifications.
Based upon the previous rationales (Zaman et al., 2013) , we obtained CNV data and gene expression information for 59 breast cancer tissues from Cancer Cell Line Encyclopedia (CCLE).
The Genomic Identification of Significant Targets in Cancer (GISTIC 2.0) was used to calculate the G-scores for each gene (Mermel et al., 2011) . As previously described (Mermel et al., 2011; Zaman et al., 2013) , we only considered the amplified genes with G-score > 0.3 and expression level among top 50% in each cell line. Finally, we obtained 3409 amplified genes in 59 breast cancer cell lines, with 535 amplified genes containing phosSNPs. Using the human proteome as the background, the hypergeometric distribution based statistical analysis showed that the phosSNPs were significantly enriched in amplified genes of breast cancers (E-ratio = 1.78, p-value = 9.54E-45). This result demonstrate that genes with phosSNPs might have a relatively higher probability to be amplified in cancers.
In the phosSNP-associated kinase-substrate network, we observed that ~28.1% (5081 out of 18056 interactions) of KSRs belong to protein tyrosine kinase signaling. Among all TK signaling events, ~73.1% (3716 out of 5081 TK interactions) of KSRs were found to be influenced by phosSNPs, which demonstrated that the TK signaling was more likely to be associated with phosSNPs. Recently, Li et al. (2012a) performed systematic analyses on protein tyrosine signaling network in cancers. The results showed that cancer signaling preferentially employs phosphotyrosine (pTyr) substrates that contain kinase domains or SH2/PTB domains and pTyr sites that were detected in more tumor samples. In this regard, we tried to explore whether phosSNPs could influence the TK signaling in cancers. To address this question, we mapped the phosSNPs into the dataset of TK circuits from lung cancers (Li et al., 2012a) . While a TK circuit contains three parts including pTyr site, tyrosine kinase, and SH2/PTB protein, only TK circuits with phosSNP-influenced KSRs were reserved for further analysis.
Finally, we obtained 344 lung cancer-related TK circuits that were influenced by phosSNPs (Supplementary Table S10 ). Among the 344 TK circuits, 228 TK circuits were mediated by high frequency cancer (HFC) pTyr sites that were detected in more than one cancer samples. The other 116 TK circuits were linked to low frequency cancer (LFC) pTyr sites that were detected in only one cancer sample (Supplementary Table S10 ). The statistical analysis revealed that phosSNPs were significantly associated with TK circuits that linked to HFC pTyr sites rather than LFC pTyr sites (E-ratio =2.58, p-value = 4.52E-17; Yates' chi-squared test). Furthermore, Li et al. (2012a) have defined two types of pTyr substrates, dual-role substrates (DRSs) and single-role substrates (SRSs), based on the existence of one or multiple kinase domains or SH2/PTB domains in a substrate. The statistical analysis revealed that the HFC pTyr sites are significantly more enriched in DRSs than SRSs in lung cancers (Li et al., 2012a) . Here, we also studied whether the phosSNPs are associated with DRSs or SRSs in lung cancers. Among HFC TK circuits, we obtained 88 TK circuits with DRSs and 140 TK circuits with SRSs (Supplementary Table S10 ). Statistical analysis demonstrated that phosSNPs preferentially occurred in DRS-containing TK circuits (E-ratio = 3.99, p-value = 2.16E-24;
Yates' chi-squared test). This could be explained that proteins with multiple kinase domains or SH2/PTB domains were commonly involved in signaling pathway, while phosSNPs might alter the phosphorylation states of the substrates, rewire the phosphorylation signaling, and further affect the cancer susceptibility. 
Discussion
Reversible phosphorylation plays an essential role in almost all biological processes and pathways. Recently, the rapid progress in phosphoproteomics using high-throughput mass spectrometry (HTP-MS) has enabled the identification of thousands of phosphorylated substrates from one sample (Olsen et al., 2006; Macek et al., 2009; Nilsson, 2012) . Thus, an efficient means of retrieving useful information from the flood of data has emerged as a critical goal. In particular, systematic analysis of the phosphoproteomic data in the context of genetic content would advance our understanding of the molecular mechanisms and regulatory processes underlying phosphorylation, including that takes place in individual populations. At the same time, genomic studies with next-generation DNA sequencing (NGS) techniques have characterized an extremely large number of germline SNPs and somatic mutations (Greenman et al., 2007; Manolio et al., 2008;  1000 Genomes Project Consortium, 2010; Forbes et al., 2010) . Systematic analysis of the GVs that reconfigure the phosphorylation network will form a link between phosphoproteomics and genomics, and thus will be helpful for understanding how GVs determine both disease susceptibility and therapeutic response in different populations.
Based on the hypothesis that the phosphorylation-associated mutation rate is significantly different to the gene-wide mutation rate, Reimand and Bader (2013) developed a gene-centric algorithm and identified 44 genes with unexpected pSNVs, including 15 known cancer genes, that locate in the kinase domains or flanking regions of phosphorylation sites. However, this statistical model is not applicable to the analysis of phosSNPs, because the mutation rate is difficult to calculate from SNP data sets. Also, SNVs located in the flanking regions of phosphorylation sites may only rarely change the phosphorylation status. For example, we observed that 1049291 nsSNPs located in at least one PSP(15, 15) region. However, only 9606 (~0.9%) of these nsSNPs were predicted to be potential phosSNPs. Thus, the prediction of exact nsSNPs that influence phosphorylation is much more helpful for the purpose of further experimental analysis. Moreover, although it is well known that kinase activity can be changed by GVs located in catalytic domains, it has remained unclear whether GVs alter the substrate specificity of kinases. In contrast, our results suggest that kinase specificity is dramatically changed by phosSNPs in substrates, even without any phosSNPs in the kinases ( Figure 3B ). In this work, we developed a SNP-centric approach by directly predicting 9606 potential phosSNPs that change the phosphorylation pattern. To evaluate the prediction accuracy, we manually collected 11 experimentally identified phosSNPs from the scientific literature (Supplementary Table S9 ). In the absence of any filters, only sequence-based prediction with GPS 2.1 predicted all the phosSNPs as positive hits. However, such a prediction is of limited use because of the high number of false positive predictions. When the experimental phosphorylation information was taken into consideration, seven known phosSNPs were predicted (Supplementary Table S9 ).
When the PPI information was added as well, there were still 4 phosSNPs recalled (Supplementary Table S9 ), whereas the number of false positive hits was greatly reduced (Table 1) . In this regard, although the method is much simpler, without the utilization of any statistical models, the performance is still highly valuable. Unexpectedly, known disease-associated SNPs were found to be significantly present in these results, with a 2.18-fold enrichment (Supplementary Table S6 ).
Based on the predicted phosSNPs, we also constructed a human phosSNP-associated kinasesubstrate network and showed that cancer genes and drug targets were both over-represented.
Further analysis demonstrated that the proteins in the network are highly involved in a number of signaling and cancer pathways. For example, there are 79 genes in the cancer pathway of chronic myeloid leukemia (KEGG ID: hsa05220), with 56 of them included in the phosSNP-associated network ( Figure 7) . Thus, the cancer pathways can be dramatically altered by phosSNPs. In particular, we observed that a number of disease-or cancer-associated genes were differentially regulated by phosSNPs in different populations. Thus, phosSNPs may influence inherited disease or cancer susceptibility by reconfiguring the phosphorylation networks in different populations.
Recently, the identification of potential "driver" mutations from the cancer genome sequencing data has emerged as an important topic. It is believed that a considerable proportion of somatic mutations are able to contribute to cancer progression by acting as "drivers" (Greenman et al., 2007; Haber and Settleman, 2007; Carter et al., 2009) . Because cancers are complex diseases and attributed to multiple genes and/or somatic mutations, recent analyses have been focused on identifying "mutated driver pathways" rather than single genes or mutations (Wood et al., 2007; Vandin et al., 2012) , e.g. functional mutations in phosphorylation signaling pathways (Reimand and Bader, 2013) . In these studies, all of the known SNPs were removed and the remaining data were regarded as somatic mutations for the further detection of drivers. A hidden assumption underlying these studies is that most SNPs are non-functional and do not contribute to cancer development. Indeed, only a small proportion of nsSNPs (0.91%) were predicted as phosSNPs in this study.
However, the result is still a comparatively large number versus somatic mutations, because it was estimated that there are <15 driver mutations in an individual tumor (Wood et al., 2007) . In particular, our results demonstrated that both phosSNPs and phosCMs preferentially occur in cancer genes, whereas known cancer genes were more significantly enriched in phosSNP-containing proteins than phosCM-associated proteins in most types of cancer ( Figure 5 ). In addition, a considerable number of substrates, especially cancer genes, contain both phosSNPs and phosCMs (Supplementary Figure S3) and cannot be distinguished from the kinase-substrate networks (Figure 6 ). In this regard, it is possible that phosSNPs may influence cancer susceptibility by driving tumor progression together with somatic mutations. Further analyses showed that phosSNPs were significantly enriched in amplified genes of breast cancers, while the phosSNPs in tyrosine signaling of lung cancer were found to be significantly associated with TK circuits that linked to HFC pTyr sites and DRS-containing TK circuits.
Taken together, the results presented provide a systematic analysis of nsSNPs that influence protein phosphorylation and show that phosSNPs are significantly implicated in inherited diseases and cancers by dramatically reconfiguring the kinase-substrate phosphorylation network. These results not only highlight the potential roles of phosSNPs in driving cancer progression, but also provide a useful resource for further experimental consideration. 
Experimental procedures
The SNP data sets
The human SNPs with map summaries were downloaded from the NCBI ftp server (dbSNP Build 141, RefSNP docsums in ASN.1 flat format) on September 17, 2014 (Sherry et al., 2001 ). In total there were 62386627 SNPs, including 1705956 cSNPs with 1060070 missense nsSNPs. In this work, we only considered nsSNPs that induce changes in amino acid residues. The nsSNPs in other forms of mutation, such as frameshift and stop-gained variations, were discarded.
To search for phosSNP-disease relations, we first downloaded 153839 disease-associated SNPs from the GWASdb (Li et al., 2012b) . Also, the SNPs with annotated disease information were obtained from the ClinVar dataset (November 14, 2014) (Landrumet al., 2014) in the NCBI ftp server, including 260112 entries with 36371 unique missense nsSNPs.
For the population analysis, the cSNPs in the 1000 Genomes Project were downloaded on June 1, 2013 (Phase I Release v3) (1000 Genomes Project Consortium, 2010 . In total, we obtained 325159 cSNPs along with reference allele frequencies from four ancestry-based super population groups (AMR, Ad Mixed American; ASN, East Asian; AFR, African; EUR, European).
The sequence data sets
We downloaded 72813 human protein sequences from the RefSeq database (NCBI Homo sapiens Annotation Release 66) on September 25, 2014 (Pruitt et al., 2007) . These sequences were regarded as the benchmark sequence data set for identifying phosSNPs. Also, we obtained 101075 human protein sequences from the Ensembl database (Version 69, November 26, 2013) (Flicek et al., 2013) for the purpose of identifying phosCMs. As previously described (Ren et al., 2010) , the redundancy in the RefSeq and Ensembl proteins was not cleared.
In a previous study (Song et al., 2012) , we prepared a non-redundant sequence data set from the UniProt database (on April 6, 2010) (UniProt Consortium, 2013) with 81733 unique proteins in Homo sapiens. For the network analysis, we mapped all of the Refseq proteins to UniProt sequences by the BLAST program with a stringent threshold (E-value ≤ 1E-30, Identities ≥ 70%) (Johnson et al., 2008) . For each RefSeq protein, the best hit was preserved when it met the threshold. In total, these RefSeq proteins were mapped to 28315 UniProt sequences. Analogously, the Ensembl proteins were also mapped to UniProt sequences for the network analysis.
The data sets on the phosphorylation sites and PPIs
Previously, we collected 145646 experimentally identified phosphorylation sites in 28457 substrates for five eukaryotic species, whereas in this work, 60816 phosphorylation sites of 10253 human proteins were collected (Song et al., 2012) . Moreover, we integrated 59481 experimentally identified PPIs (Exp. PPIs) among 12221 human proteins, and obtained 1212607 pre-calculated PPIs (STRING PPIs) for 16523 human proteins from the STRING database (Jensen et al., 2009; Song et al., 2012) . The sequences of phosphorylated and interacting proteins were prepared in the UniProt FASTA format (Jensen et al., 2009; UniProt Consortium, 2013) .
The data sets on somatic cancer mutations
The somatic CMs were downloaded from the data repository of the International Cancer Genome Consortium (ICGC) (http://dcc.icgc.org, Data Release 14, September 26, 2013) (Hudson et al., 2010) . Somatic CMs of 26 types of cancers sequenced from the different populations were obtained. First, the missense CMs were extracted out and directly mapped to their corresponding protein sequences from Ensembl (Flicek et al., 2013) . Because the cancer genome sequencing was still not completed, several types of cancers only contained very limited number of sequenced somatic CMs. Thus, ultimately, only 12 types of cancers with more than 10000 missense CMs were selected for further analyses. Because the corresponding SNPs were not available for these cancer samples, we selected population-specific SNPs for each cancer to compare phosSNPs and phosCMs in the different populations. We chose the AMR for UCEC-US, COAD-US, LUSC-US, BRCA-US, READ-US, KIRC-US, GBM-US, OV-US, and PACA-CA, the ASN for LAML-KR and LINC-JP, and the EUR for BRCA-UK.
Computational identification of phosSNPs and phosCMs
Based on the map summaries of human SNPs, we first picked out all RefSeq proteins with at least one nsSNP. Then we generated nsSNP-containing proteins (mutated proteins) from the benchmark sequences. As previously described (Ren et al., 2010) , each of the mutated sequences contains only one nsSNP, whereas the combined effects of multiple nsSNPs were not analyzed in GPS 2.1 (Xue et al., 2011) was chosen to predict ssKSRs for the original and mutated proteins, respectively. Because GPS only predicts kinase-specific sites at the PK cluster level, we manually formed links of 407 human kinases with their corresponding predictors in GPS 2.1 (Song et al., 2012) . Then the exact kinases of the predicted phosphorylation sites were characterized.
Furthermore, the known phosphorylation sites and PPIs were adopted as two filters to remove potentially false positive hits for the prediction of ssKSRs. By comparison of the prediction results for the original and mutated human proteins, the phosSNPs were identified.
Previously, we classified all of the predicted phosSNPs into five categories (Ren et al., 2010) as follows. (i) Type I: create (+) or remove (-) a phosphorylation site at a phosphorylatable position;
(ii) Type II: create (+) or disrupt (-) one or multiple adjacent phosphorylation sites; (iii) Type III: change the kinase type for one or multiple adjacent phosphorylation sites; (iv) Type IV: induce a change in kinase type at a phosphorylatable position; (v) Type V: generate a stop codon to disrupt following phosphorylation sites. Because Type V phosSNPs occupied only ~0.7% of the total results (Ren et al., 2010) and truncated transcripts heavily influence protein function beyond phosphorylation, this type was not calculated or included thereafter. Using the same procedure, we also identified and classified potential phosCMs for each cancer type. The predicted datasets for phosSNPs and phosCMs were available at http://phossnp.biocuckoo.org/dataset.php.
Network construction and analysis
To avoid redundancy, all phosSNP-or phosCM-containing proteins were mapped to UniProt sequences. Because a kinase is able to phosphorylate a substrate at multiple sites, there can be multiple ssKSRs between the kinase and substrate. For the network construction, we only considered the KSR, and multiple ssKSRs between a kinase and a substrate were counted as a single KSR. Based on the predicted ssKSRs for the original and mutated proteins, a human phosSNP-or phosCM-associated kinase-substrate phosphorylation network was re-constructed and visualized by Cytoscape 2.8.3 (Shannon et al., 2003) . In the network, the nodes are kinases or substrates, whereas the edges are KSRs. As previously described (Song et al., 2012) (Bader and Hogue, 2003) , a plugin of Cytoscape, to detect molecular complexes in the phosSNP-associated network. To analyze the impact of phosSNPs on the network topology, Cytoscape plugin cytoHubba v1.6 (Lin et al., 2008) was employed to separately calculate the topological features in original and mutated networks, including degree, maximal clique centrality (MCC), maximum neighborhood component (MNC), bottleneck (BN), and betweenness. As previously described (Jin et al., 2007; Wang et al., 2007; Zaman et al., 2013) , we picked out top 200 genes (~10%) with most degrees as hub genes in original and mutated networks, respectively. Then the above five topological features for hub genes were also calculated, while non-parametric Wilcoxon signed-rank test was performed to statistically compare the topological changes of degree, MCC, MNC, BN, and betweenness (p-value < 0.01). Based on the annotation information of the 1000 Genomes Project, we also constructed and analyzed population-specific phosSNP-associated networks.
Identification of gene amplifications in breast cancer cell lines
Previously, the procedure for identifying gene amplification was described (Zaman et al., 2013) . Following this method, the pre-segmented CNV dataset identified by Affymetrix SNP6.0 arrays and gene expression information for 59 breast cancer cell lines were downloaded from CCLE (http://www.broadinstitute.org/ccle/home, published on September 29, 2012). The corresponding marker file for Affymetrix SNP6.0 data, which was annotated with human reference genome 31, was downloaded from National Cancer Institute (NCI, https://wiki.nci.nih.gov). The gene amplification data processing software GISTIC 2.0 was downloaded from Cancer Cell Line Encyclopedia (Mermel et al., 2011) .
The copy number variation dataset and the marker file were imported into GISTIC 2.0 to calculate the G-scores with the default parameters (Mermel et al., 2011) . As previously described (Zaman et al., 2013) , we identified amplified genes with the threshold of a G-score > 0.3 and expression level among top 50% in each cell line. The GISTIC results were further mapped to USCS human genome to obtain the gene names and UniProt accession numbers. Finally, we totally identified 3409 amplification genes in 59 breast cancer cell lines.
The statistical analysis of enrichment
From the Cancer Gene Census (Futreal et al., 2004) , in total we obtained 474 well documented cancer genes. We also obtained 555 cancer genes as a secondary data set (Reimand's data) from a recently published analysis (Reimand and Bader, 2013) . Only 442 and 467 cancer genes in the two data sets were successfully mapped to UniProt proteins, respectively. Furthermore, we downloaded the protein sequences of 4906 drug targets from the DrugBank database (Wishart et al., 2008) , and 1919 of them were mapped to UniProt sequences. The proteins in the phosSNP-associated network (network proteins) were mapped to the three data sets for the purpose of statistical enrichment analyses, with a hypergeometric distribution .
Moreover, we retrieved the GO annotations of 28315 UniProt proteins (UniProt, 2013) . A total of 18911 UniProt sequences, including 2375 network proteins, were annotated with at least one GO term. The KEGG was used to map UniProt proteins to the biological pathways (Kanehisa et al., 2004 ). There were 6824 UniProt proteins, including 1355 network proteins annotated with at least one KEGG pathway entry. In addition, because the FunDO (Functional Disease Ontology), an online service for exploring gene-disease relations, only adopts a Gene ID as the input (Schriml et al., 2012) , we used the ID Mapping tool in UniProt database (UniProt, 2013) and obtained Gene IDs for 2544 network proteins. We directly submitted the Gene IDs to FunDO for the statistical enrichment analysis of the DO items (p-value < 1E-10) (Schriml et al., 2012) . Table S9 ). Tables   Table 1 The The hypergeometric distribution was performed. p-value < 1E-14. 
